UQ's potential COVID-19 vaccine enters a new phase, and over 10,000 compounds have been tested to identify drug candidates that may help treat the disease.
Using drugs to inhibit two separate proteins, researchers found that they could effectively kill melanoma cells by inducing apoptosis.
Scientists engineered bacteria to live in the guts of honey bees and act as biological factories, pumping out medicines protecting the bees against both Varroa mites and deformed wing virus.
Two new studies out of the US show promise for the treatment of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19).
Engineered to address the rigorous requirements and complexity of biologics manufacture, Sartorius's BIOSTAT STR Generation 3 bioreactor is a robust industrial platform consisting of hardware, software and consumables for single-use process development and commercial biomanufacturing.
A clinical trial of the drug, known as VYONDYS 53 (golodirsen), established that it was well tolerated and acted to restore dystrophin protein.
Life Sciences Queensland (LSQ) has formed a partnership with India's Association of Biotechnology Led Enterprises (ABLE).
The DELRIN SC698 resin with integrated lubrication can help improve patient comfort and ease of use by ensuring smooth actuation of high-load drug delivery devices like inhalers, injectors and pumps.
The treatment has been found to completely kill a bacterial infection that can be deadly to patients with cystic fibrosis and other chronic lung conditions such as bronchiectasis.
Singaporean scientists have discovered four potential drug compounds that target hepatocellular carcinoma (HCC), the most common type of liver cancer.
A drug used to treat high blood pressure may alleviate anxiety induced by long-term heavy alcohol use, and also halt the damage such drinking can cause to the brain's ability to grow new cells.
With novel perfusion technology, livers — even injured livers — can now be kept alive outside of the body for an entire week.
Life sciences company QBiotics has announced positive results from its first-in-human Phase I clinical trial of its anticancer pharmaceutical, tigilanol tiglate (EBC-46).
The drug candidates may be useful for treating a broad array of conditions, and suggest a new pathway that links normal ageing to Alzheimer's disease.
The Hudson Institute of Medical Research has completed a preclinical study investigating Invion's Photosoft compound on mice with ovarian cancer — with promising results.